BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 37761908)

  • 1. Predicting Patterns of Distant Metastasis in Breast Cancer Patients following Local Regional Therapy Using Machine Learning.
    Shiner A; Kiss A; Saednia K; Jerzak KJ; Gandhi S; Lu FI; Emmenegger U; Fleshner L; Lagree A; Alera MA; Bielecki M; Law E; Law B; Kam D; Klein J; Pinard CJ; Shenfield A; Sadeghi-Naini A; Tran WT
    Genes (Basel); 2023 Sep; 14(9):. PubMed ID: 37761908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Machine learning approaches for prediction of early death among lung cancer patients with bone metastases using routine clinical characteristics: An analysis of 19,887 patients.
    Cui Y; Shi X; Wang S; Qin Y; Wang B; Che X; Lei M
    Front Public Health; 2022; 10():1019168. PubMed ID: 36276398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retrospective analysis of metastatic behaviour of breast cancer subtypes.
    Savci-Heijink CD; Halfwerk H; Hooijer GK; Horlings HM; Wesseling J; van de Vijver MJ
    Breast Cancer Res Treat; 2015 Apr; 150(3):547-57. PubMed ID: 25820592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients].
    Zhang P; Xu BH; Ma F; Li Q; Yuan P; Wang JY; Zhang P
    Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):381-4. PubMed ID: 21875471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Marked lymphovascular invasion, progesterone receptor negativity, and high Ki67 labeling index predict poor outcome in breast cancer patients treated with endocrine therapy alone.
    Kurebayashi J; Kanomata N; Shimo T; Yamashita T; Aogi K; Nishimura R; Shimizu C; Tsuda H; Moriya T; Sonoo H
    Breast Cancer; 2014 Mar; 21(2):214-22. PubMed ID: 22689016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CDO1 promoter methylation is a biomarker for outcome prediction of anthracycline treated, estrogen receptor-positive, lymph node-positive breast cancer patients.
    Dietrich D; Krispin M; Dietrich J; Fassbender A; Lewin J; Harbeck N; Schmitt M; Eppenberger-Castori S; Vuaroqueaux V; Spyratos F; Foekens JA; Lesche R; Martens JW
    BMC Cancer; 2010 Jun; 10():247. PubMed ID: 20515469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring the relationships between hormone receptor, HER2 status, and bone involvement in the first distant metastases of in Chinese breast cancer patients who lacked HER2 targeted therapy.
    Jia Z; Dai M; Shang Y; Li Y; Li Z
    BMC Cancer; 2023 Jan; 23(1):93. PubMed ID: 36703144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of postoperative disease-free survival and brain metastasis for HER2-positive breast cancer patients treated with neoadjuvant chemotherapy plus trastuzumab using a machine learning algorithm.
    Takada M; Sugimoto M; Masuda N; Iwata H; Kuroi K; Yamashiro H; Ohno S; Ishiguro H; Inamoto T; Toi M
    Breast Cancer Res Treat; 2018 Dec; 172(3):611-618. PubMed ID: 30194511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A machine learning-Based model to predict early death among bone metastatic breast cancer patients: A large cohort of 16,189 patients.
    Xiong F; Cao X; Shi X; Long Z; Liu Y; Lei M
    Front Cell Dev Biol; 2022; 10():1059597. PubMed ID: 36568969
    [No Abstract]   [Full Text] [Related]  

  • 10. Magnetic resonance imaging radiomics predicts preoperative axillary lymph node metastasis to support surgical decisions and is associated with tumor microenvironment in invasive breast cancer: A machine learning, multicenter study.
    Yu Y; He Z; Ouyang J; Tan Y; Chen Y; Gu Y; Mao L; Ren W; Wang J; Lin L; Wu Z; Liu J; Ou Q; Hu Q; Li A; Chen K; Li C; Lu N; Li X; Su F; Liu Q; Xie C; Yao H
    EBioMedicine; 2021 Jul; 69():103460. PubMed ID: 34233259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic Factors and Survival According to Tumor Subtype in Women With Breast Cancer Brain Metastases.
    Lopes S; Vieira I; Abreu M; Pousa I; Ferreira A; Sousa S; Pereira D
    Curr Probl Cancer; 2022 Dec; 46(6):100866. PubMed ID: 36179388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breast cancer subtypes predict the preferential site of distant metastases: a SEER based study.
    Wu Q; Li J; Zhu S; Wu J; Chen C; Liu Q; Wei W; Zhang Y; Sun S
    Oncotarget; 2017 Apr; 8(17):27990-27996. PubMed ID: 28427196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Machine Learning Frameworks to Predict Neoadjuvant Chemotherapy Response in Breast Cancer Using Clinical and Pathological Features.
    Meti N; Saednia K; Lagree A; Tabbarah S; Mohebpour M; Kiss A; Lu FI; Slodkowska E; Gandhi S; Jerzak KJ; Fleshner L; Law E; Sadeghi-Naini A; Tran WT
    JCO Clin Cancer Inform; 2021 Jan; 5():66-80. PubMed ID: 33439725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of early distant metastasis in women with breast cancer.
    Rosa Mendoza ES; Moreno E; Caguioa PB
    J Cancer Res Clin Oncol; 2013 Apr; 139(4):645-52. PubMed ID: 23283528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative digital histopathology and machine learning to predict pathological complete response to chemotherapy in breast cancer patients using pre-treatment tumor biopsies.
    Saednia K; Lagree A; Alera MA; Fleshner L; Shiner A; Law E; Law B; Dodington DW; Lu FI; Tran WT; Sadeghi-Naini A
    Sci Rep; 2022 Jun; 12(1):9690. PubMed ID: 35690630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM 9906 trial.
    Martin M; Brase JC; Calvo L; Krappmann K; Ruiz-Borrego M; Fisch K; Ruiz A; Weber KE; Munarriz B; Petry C; Rodriguez CA; Kronenwett R; Crespo C; Alba E; Carrasco E; Casas M; Caballero R; Rodriguez-Lescure A
    Breast Cancer Res; 2014 Apr; 16(2):R38. PubMed ID: 24725534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pattern of Local Recurrence and Distant Metastasis in Breast Cancer By Molecular Subtype.
    Wu X; Baig A; Kasymjanova G; Kafi K; Holcroft C; Mekouar H; Carbonneau A; Bahoric B; Sultanem K; Muanza T
    Cureus; 2016 Dec; 8(12):e924. PubMed ID: 28090417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel immunohistochemistry-based signatures to predict metastatic site of triple-negative breast cancers.
    Klimov S; Rida PC; Aleskandarany MA; Green AR; Ellis IO; Janssen EA; Rakha EA; Aneja R
    Br J Cancer; 2017 Sep; 117(6):826-834. PubMed ID: 28720841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer.
    Hatzis C; Pusztai L; Valero V; Booser DJ; Esserman L; Lluch A; Vidaurre T; Holmes F; Souchon E; Wang H; Martin M; Cotrina J; Gomez H; Hubbard R; Chacón JI; Ferrer-Lozano J; Dyer R; Buxton M; Gong Y; Wu Y; Ibrahim N; Andreopoulou E; Ueno NT; Hunt K; Yang W; Nazario A; DeMichele A; O'Shaughnessy J; Hortobagyi GN; Symmans WF
    JAMA; 2011 May; 305(18):1873-81. PubMed ID: 21558518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of Oncotype DX score in clinical management for T1 estrogen receptor positive, HER2 negative, and lymph node negative breast cancer.
    Nguyen TTA; Postlewait LM; Zhang C; Meisel JL; O'Regan R; Badve S; Kalinsky K; Li X
    Breast Cancer Res Treat; 2022 Apr; 192(3):509-516. PubMed ID: 35084624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.